Credits: Canva
As per the latest data released by Transforming Access to Student Outcomes in Higher Education (TASO) and the Policy Institute at King's College London, the number of UK students reporting mental health difficulties tripled. The estimate reveals that around 300,000 students could now be experiencing mental health struggles. Of the total, 18% of students reported some kind of mental health issue in 2024.
As per the reports, this estimate is triple what was reported in 2017, where it was at 6%. Experts also say that Covid-19 pandemic is "often considered to have contributed to this, it does not explain the ongoing rise in mental health difficulties." Another reason could also be the "changing definition and increasing openness about mental health" which has led to a rise in numbers. The report notes, "This trend pre-dates the Covid-19 pandemic and the cost-of-living crisis. Although these factors play a part in students' deteriorating mental health, they cannot therefore be the only explanation."
The report drew data collected over the latest Student Academic Experience Survey of 93,212 students. From the survey, it was found that there exist significant disparities between demographic groups, with women being twice as likely to report mental health difficulties, about 22% as compared to men, at 11%.
The results revealed that students who identified as LGBTQ experienced the highest rates of mental health challenges. This has actually lessened the hope that conditions for LGBTQ students are improving, which may not have been a positive case.
Of them, 42% are bisexual and lesbian students, whereas last year it was 35% and 32% respectively. The report also noted that mental health difficulties among lesbian women and gay men rose three times the rate of straight people, and among bisexual and asexual people, it was twice as high. For trans students, the number jumped from 25% in 2023 to 40% in 2024.
As per the Child Mind Institute, being LGBTQ+ does not cause mental health problems, but because these kids often face factors like rejection, discrimination and violence, they are at a higher risk of challenges including depression, anxiety, and even attempting suicide.
A UTAH Health study quotes Anna Docherty, PhD, LP, assistant professor of psychiatry at Huntsman Mental Health Institute that, "likely with any identity, feeling different - or worse, unaccepted as you are is a significant risk factor of mental health struggle." The data reveals that LGBTQ+ teens are six times more likely to experience symptoms of depression than non-LGBTQ+ identifying teens. They are also more than twice as likely to feel suicidal and more than four times as likely to attempt suicide. In the US alone, 48% of transgender adults report that they have considered suicide in the last year, compared to 4% of the overall population.
TASO's academic lead and professor of public policy at King's College London, Michael Sanders said, "LGBTQ students and women bear the brunt of the rise in declining mental health and urgent action is needed to understand and address these trends."
Credit: University of Oxford/Canva
The number of confirmed Ebola cases in the Democratic Republic of Congo (DRC) has reached 3,200, including a death toll of 1,405, according to the latest official data.
Caused by the rare Bundibugyo strain, the outbreak is the third-largest on record.
Amid the worsening outbreak, researchers have reached an important scientific milestone in vaccination. The first human volunteer has received an experimental vaccine targeting the Bundibugyo strain of Ebola, marking the world's first Phase I clinical trial, the University of Oxford said.
The vaccine, known as ChAdOx1 BDBV, uses the same viral vector platform that was employed for the Oxford-AstraZeneca COVID-19 vaccine.
Professor Katrina Pollock, chief investigator at the Oxford Vaccine Group, described the launch as "an important milestone" in the effort to develop protection against a virus for which no licensed vaccine currently exists.
"We welcome the start of the phase 1 clinical trial of an investigational vaccine against Ebola Bundibugyo virus disease — an important step to assess the safety and immune responses generated by the vaccine," said Tedros Adhanom Ghebreyesus, Director-General of the World Health Organization (WHO) said in a post on social media platform X.
Also read: Ebola Bundibugyo Strain: All You Should Know About The Rare Virus
ChAdOx1 BDBV, developed in collaboration with Serum Institute of India (SII), is designed specifically to protect against the Bundibugyo strain of Ebola.
It is reportedly the first of four Bundibugyo Ebola vaccine candidates currently under development to enter human clinical trials.
The vaccine uses a genetically modified chimpanzee adenovirus (ChAdOx1)—a harmless virus that normally causes the common cold in chimpanzees—as a delivery vehicle.
Scientists have inserted genetic material from the Ebola Bundibugyo virus into this harmless virus. Once injected in humans, the modified virus trains the immune system to recognize the Ebola virus and produce protective antibodies and fight the infection.
The vaccine has already shown promising results in mice and macaque monkeys and is being manufactured to clinical standards by the SII, which has already produced and stockpiled around 620,000 doses. Based on preclinical data, the UK's MHRA approved the vaccine to proceed to human trials.
Read More: Ebola Outbreak: The Unique Symptoms Seen In Patients Infected With Bundibugyo
The Oxford researchers will recruit 50 healthy adults aged 18 to 55 years in the UK for the Phase 1 trial.
Scientists are also working with partners in Uganda to prepare future clinical trials in Africa. Participants will be monitored for one year, although researchers expect to know much sooner whether the vaccine generates the desired immune response and whether any unexpected side effects occur.
Researchers are also exploring preventive vaccination strategies for healthcare workers and people who have been in close contact with infected patients.
One such approach is ring vaccination, in which individuals surrounding a confirmed Ebola case are vaccinated or given preventive treatment to stop further spread.
The goal is to develop a single-dose vaccine, similar to the licensed vaccine against the Ebola Zaire strain. Scientists believe that both antibodies and T cells—immune cells that recognize and destroy infected cells—will play an important role in protection, although long-term immunity against the Bundibugyo strain is not yet fully understood.
"Pre-clinical models for these pathogens have already shown that a single-dose vaccine can protect animals. So, we are optimistic that a one-shot vaccine is achievable," Prof Teresa Lambe, Head of Vaccine Immunology, Oxford Vaccine Group, Pandemic Sciences Institute, University of Oxford, told The Indian Express.
Credit: AI
The American Red Cross has declared a national blood supply crisis for only the second time in its history, warning that blood donations have dropped to a four-year summer low while demand from hospitals continues to rise.
The organization says the shortage has reached a point where patient care could be affected if donations do not increase immediately.
According to the Red Cross, the crisis is being driven by a combination of fewer blood donations during the summer months and higher demand for blood products, particularly during the peak trauma season.
One of the biggest concerns is the shortage of type O positive blood, the most commonly transfused blood type in the United States.
The American Red Cross said it currently has less than a one-day national supply of O-positive blood. They have limited distributions to individual hospitals to ensure the blood type is available for the most life-threatening emergencies.
Supplies of O-negative blood, the universal blood type used in trauma situations when there is no time to determine a patient's blood group, are also not sufficient.
The Red Cross noted that many blood collection organizations across the country are reporting similar challenges this year.
Also read: US Billionaire Undergoes Total Plasma Exchange: Know What It Is
Summer has always been one of the most difficult seasons for maintaining a stable blood supply. Schools and colleges, which frequently host blood drives, are closed, while vacations and holiday travel often disrupt regular donation schedules.
At the same time, hospitals continue to require blood due to surgeries, cancer treatments, childbirth complications, chronic illnesses, and trauma patients.
The Red Cross said these seasonal challenges have intensified this year, resulting in the lowest level of summer donations seen in four years.
In its announcement, the American Red Cross said, "The American Red Cross has declared only the second national blood supply crisis in its history after blood donations fell to a four-year summer low, deepening an emergency shortage that threatens the availability of lifesaving blood for patients across the country."
The organization also emphasized the urgency of public participation, stating, "Just three more donors at each blood drive this summer can end this crisis and stabilize the blood supply."
Encouraging immediate action, the Red Cross added, "Don't wait. Those who may be eligible are urged to book an appointment now."
Also read: Women Are Three Times More Likely Than Men To Develop Anemia
The Red Cross warned that some patients are already experiencing delays in receiving blood transfusions as supplies become increasingly strained.
By prioritizing blood distribution to the most urgent cases, hospitals may face difficult decisions about how limited supplies are allocated.
Healthcare providers rely on a steady stream of donations because blood has a limited shelf life. Red blood cells can generally be stored for about six weeks, while platelets last only a few days, making continuous donations essential for maintaining adequate supplies.
The American Red Cross has urged all eligible donors, regardless of blood type, to schedule a blood donation as soon as possible. Officials believe that even a slight increase in donations at blood drives across the country could quickly stabilize blood inventory.
Credit: AI
Legendary singer-songwriter Carly Simon has shared that she has been diagnosed with Parkinson's disease and recently underwent treatment for skin cancer, offering fans a personal explanation for her years-long absence.
In a heartfelt statement released on July 27, the 83-year-old You're So Vain singer revealed that she has been privately navigating multiple health challenges while continuing to work on new music.
The announcement comes just weeks before the release of Comes in Waves, her first album of original material since 2008.
Addressing her prolonged absence from public life, Simon wrote, "So many people have written to me, kindly wondering about my relative silence, asking how I am and what I have been doing."
She then revealed the reason behind her disappearance. She said that she has been learning how to live with Parkinson's disease.
Simon explained that her health struggles initially began with severe arthritis in her hips and knees, leading to joint replacement surgeries. However, when her mobility continued to worsen after surgery, she sought further evaluation at the Mayo Clinic, where she was diagnosed with Parkinson's disease.
Also read: Neurological Disorders Emerging As India's Next Major Public Health Challenge, Say Experts
Simon also spoke candidly about living with Parkinson's, emphasizing that the disease affects each person differently.
She described experiencing good days and difficult days, adding that she is receiving treatment and adapting to a new routine while continuing to prioritize her health and creative work. Fatigue, mobility issues and other symptoms have become part of her daily life, she said
Despite the diagnosis, Simon stressed that she remains committed to making music. "I have not stopped living, and I have not stopped working," she said.
She shared that spending more time at home allowed her to revisit unfinished songs and complete new material, resulting in Comes in Waves, which she describes as a project that helped sustain her through some of her most challenging years.
Alongside Parkinson's disease, Simon disclosed that she was treated for basal cell carcinoma, the most common form of skin cancer. Although the cancer was successfully removed through surgery, she admitted that the procedure altered her appearance and affected her confidence.
Reflecting on the experience with characteristic wit, she referenced one of her most iconic songs, noting that concerns about her appearance made it difficult to return to the spotlight.
Parkinson's disease is a progressive neurological disorder that primarily affects movement. It develops when nerve cells in the brain that produce dopamine gradually deteriorate. Common symptoms include:
Although there is currently no cure, medications, physical therapy and lifestyle interventions can help manage symptoms and improve quality of life.
By sharing her diagnoses, Simon joins a growing number of public figures who have spoken openly about living with Parkinson's disease, helping raise awareness about the condition while reducing stigma.
© 2024 Bennett, Coleman & Company Limited